Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients

• Published in: Medicine (Baltimore) 2022-02, Vol.101 (5), p.e28729-e28729
• Main Authors: Ye, Fanhao, Li, Hebo, Chen, Xiaoshu, Wang, Yi, Lin, Wei, Chen, Hao, Huang, Shiwei, Han, Sisi, Guan, Fanlu, Huang, Zhouqing
• Format: Article
• Language: English
• Subjects: Aminobutyrates - therapeutic use; Angiotensin Receptor Antagonists - therapeutic use; Biphenyl Compounds - therapeutic use; Diabetes Mellitus; Drug Combinations; Heart Failure - complications; Heart Failure - drug therapy; Humans; Myocardial Infarction - complications; Myocardial Infarction - drug therapy; Observational Study; Retrospective Studies; Stroke Volume; Valsartan - therapeutic use; Ventricular Function, Left
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000028729

Objective to evaluate the clinical efficacy and safety of sacubitril valsartan in the treatment of heart failure (HF) with midrange ejection fraction after acute myocardial infarction (AMI) in diabetic patients. From January 2015 to July 2020, HF patients with diabetes mellitus complicated with AMI were retrospectively analyzed. According to the medication, they were divided into 2 groups, that is, sacubitril valsartan group (84 cases) and valsartan group (86 cases). Valsartan group took valsartan capsule (80 mg/capsule, Beijing Novartis Pharmaceutical Co., Ltd) 80 mg, qd, on the basis of routine treatment. On the basis of routine treatment, the sacubitril valsartan group took sacubitril valsartan sodium tablets (50 mg/tablet, Beijing Novartis Pharmaceutical Co., Ltd), the initial dose was 25 mg, bid, and gradually increased to the target dose according to the patient's blood pressure. After 12 months of treatment, the independent sample t test showed that the left ventricular end diastolic dimension in the sacubitril valsartan group was lower than that in the valsartan group [(47.26 ± 4.71) mm vs (50.05 ± 5.62) mm, P